Ayala Pharmaceuticals Inc Post ASCO Data Call Transcript
Good morning, and welcome to the Ayala Pharma post-2023 ASCO data conference call. (Operator Instructions) As a reminder, this conference is being recorded.
At this time, I would like to hand the call over to Tim McCarthy of LifeSci Advisors. Thank you. You may begin.
Thank you, Daryl. And thank you all for joining us on this webinar and conference call to discuss the latest RINGSIDE clinical data that were presented at ASCO. Joining me today from Ayala are Ken Berlin, President and CEO; and Dr. Andres Gutierrez, Executive Vice President and Chief Medical Officer.
Before we get started, I would draw your attention to the legal disclosures here on slide 2. The presentation today will contain forward-looking statements about Ayala's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or other future events or developments. We encourage you to review the company's filings with the SEC, which identify specific factors that may cause
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
